ABEONA THERAPEUTICS INC. Current Income Tax Expense (Benefit)
ABEONA THERAPEUTICS INC. (ABEO) reported Current Income Tax Expense (Benefit) of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-17
- ABEONA THERAPEUTICS INC. current income tax expense (benefit) for the quarter ending 2025-12-31 was -$200.00K.
- ABEONA THERAPEUTICS INC. current income tax expense (benefit) for the quarter ending 2025-09-30 was $15.20M.
- ABEONA THERAPEUTICS INC. current income tax expense (benefit) for the quarter ending 2025-06-30 was $15.50M.
- ABEONA THERAPEUTICS INC. current income tax expense (benefit) for the quarter ending 2025-03-31 was -$30.40M.
- ABEONA THERAPEUTICS INC. current income tax expense (benefit) for fiscal 2025 was $100.00K.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $15.00M derived: sum of 2 quarters · filed 2026-03-17 | $30.50M derived: sum of 3 quarters · filed 2026-03-17 | $100.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $15.20M 10-Q · filed 2025-11-12 | $30.70M derived: sum of 2 quarters · filed 2025-11-12 | $300.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $15.50M 10-Q · filed 2025-08-14 | $15.50M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$30.40M derived: 10-K 12 month − 3 quarters · filed 2026-03-17 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |